Principal Investigator
Sabrina Paganoni, MD
Massachusetts General Hospital
- 3 trials
- 1 compound
Therapeutic focus
- Amyotrophic Lateral Sclerosis
- Motor Neuron Disease
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Spinal Cord Diseases
- TDP-43 Proteinopathies
- Nervous System Diseases
- Central Nervous System Diseases
- ALS
All trials (3)
| NCT | Phase | Status | Compound | Sponsor |
|---|---|---|---|---|
| NCT05053035 | Phase 2 | Discontinued | Latozinemab | Alector Inc. |
| NCT03127514 | Phase 2 | Completed | — | Amylyx Pharmaceuticals Inc. |
| NCT02525471 | Phase 1 | Completed | — | Sabrina Paganoni, M.D. |
Compounds studied
Trial sites (24)
- New Orleans, Louisiana, United States
- Columbus, Ohio, United States
- Orange, California, United States
- Atlanta, Georgia, United States
- Baltimore, Maryland, United States
- San Antonio, Texas, United States
- Tampa, Florida, United States
- Lexington, Kentucky, United States
- Philadelphia, Pennsylvania, United States
- Phoenix, Arizona, United States
- Minneapolis, Minnesota, United States
- Dallas, Texas, United States
- Boston, Massachusetts, United States
- Iowa City, Iowa, United States
- Lincoln, Nebraska, United States
- San Francisco, California, United States
- Ann Arbor, Michigan, United States
- Seattle, Washington, United States
- St Louis, Missouri, United States
- Portland, Oregon, United States
- Gainesville, Florida, United States
- Winston-Salem, North Carolina, United States
- Worcester, Massachusetts, United States
- New York, New York, United States
Investigator and site data mirrored fromClinicalTrials.gov (public domain).